Replimune Group

Rule Changes

Seeking first-ever product approval for RP1

Patients with advanced melanoma that keeps growing after standard immunotherapy have almost nothing left to try. Replimune wants to sell them a virus that is injected straight into tumors. On July 30, an FDA expert panel voted on whether the company's trial data are solid enough to prove the drug works.

Updated 3 hours ago